Cyclacel Pharmaceuticals is a biopharmaceutical company developing oral therapies for the treatment of cancer and other serious diseases. The company has three product candidates are currently in clinical development: Sapacitabine (CYC682) for the treatment of acute myeloid leukemia (AML) in the elderly and for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia; Seliciclib (CYC202) for the treatment of lung cancer and nasopharyngeal cancer; and CYC116 for patients with solid tumors. For further information, visit the company’s Web site at www.cyclacel.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: